Living clinical guidelines represent an evolution beyond traditional static protocols by continuously integrating emerging therapeutic insights and clinical practice changes in real time. Unlike conventional guidelines that remain fixed until periodic updates, living guidelines provide a flexible, iterative framework enabling gastroenterologists to adapt their care approaches rapidly as new evidence becomes available. This adaptable methodology is particularly critical in IBD, where therapeutic landscapes are shifting rapidly due to novel biologics, small molecules, and personalized treatment strategies.

Latica’s proprietary data platform lies at the core of this study’s innovative approach. It enables the secure aggregation and de-identification of vast quantities of electronic health record (EHR) data from community gastroenterology practices, starting with Gastro Health and Allied Digestive Health, which collectively represent some of the most extensive GI practice networks within the United States. Latica’s platform excels in transforming heterogeneous and often unstructured medical documentation — including physician notes, lab results, and imaging reports — into structured, analyzable data, leveraging state-of-the-art natural language processing (NLP) and machine learning algorithms.

By tapping into this real-world evidence, the study aims to elucidate the true clinical and operational impacts of AGA’s ulcerative colitis living guideline as it is adopted in everyday outpatient settings. Key endpoints include measuring actual treatment adoption rates, the evolution of patient care pathways, and resulting clinical outcomes such as remission rates, hospitalization frequencies, and therapy adherence. This granular insight into real-world practice variations and outcomes is indispensable for closing the translational gap between guideline recommendations and tangible improvements in patient health.

AGA President Dr. Lawrence Kim underscores the necessity of this initiative, emphasizing that rapidly evolving treatment modalities necessitate robust mechanisms to monitor how guidelines perform in actual clinical environments. The real-world data generated will not only reinforce evidence-based recommendations but also inform payor strategies and healthcare policy, ultimately fostering alignment across the healthcare ecosystem to optimize resource utilization and patient care quality.

Latica CEO and co-founder Omer Dror further highlights the transformative potential borne from combining AI with expansive clinical datasets. With the power to mine granular clinical narratives and detect nuanced treatment patterns at scale, this collaboration seeks to generate evidence with unprecedented depth and precision. The study’s analytical capabilities extend beyond descriptive statistics, employing predictive modeling to anticipate patient trajectories and identify care bottlenecks, enabling proactive clinical interventions.

From a community practice standpoint, leaders like Dr. Eugenio Hernandez of Gastro Health express optimism about leveraging these innovations to measure guideline adherence and identify gaps in care. The capacity to continuously assess guideline efficacy in varied real-world patient populations allows clinicians to recalibrate and personalize therapeutic regimens, thus advancing the frontier of precision gastroenterology.

Likewise, Dr. Nadeem Baig, Chief Medical Officer of Allied Digestive Health, notes that integrating Latica’s AI-driven insights aligns seamlessly with their organization’s mission of delivering high-quality, compassionate GI care. By rigorously evaluating guideline implementation in diverse community settings, this collaborative study promises to not only elevate standardization of care but also enhance patient engagement and satisfaction through evidence-backed, data-informed clinical decision-making.

The IBD Living Guidelines Real-World Evidence Study embodies a critical nexus in the ongoing endeavor to bridge clinical research and everyday practice. Traditionally, clinical trials and guidelines have operated in somewhat insular environments, often failing to reflect the complexities and heterogeneity of community practice populations. The infusion of real-world evidence, powered by advanced AI methodologies, permits a dynamic feedback loop wherein guidelines can be continuously validated, refined, and contextualized against authentic patient experiences and outcomes.

Moreover, this initiative exemplifies the broader paradigm shift within medicine toward data-driven, precision approaches that leverage vast clinical datasets alongside machine intelligence. By moving beyond retrospective chart reviews and claims data, the utilization of comprehensive EHR-derived real-world data enables multidimensional analyses encompassing clinical nuance, therapeutic sequencing, and longitudinal patient follow-up, all at scale.

Ultimately, the collaborative framework established by AGA, Latica, Gastro Health, and Allied Digestive Health sets a new standard for how specialty societies and healthcare providers can harness digital innovation to transform chronic disease management. The insights generated through this study will not only inform future iterations of living guidelines for ulcerative colitis but will also serve as a blueprint for applying similar cutting-edge methodologies across other gastrointestinal disorders and medical specialties.

As the field of gastroenterology continues to evolve in the era of personalized medicine, initiatives such as this underscore the vital importance of integrating AI-powered real-world evidence to enhance clinical decision-making and improve patient-centered outcomes. By fostering ongoing, iterative dialogue between guideline development and real-world clinical practice, the IBD Living Guidelines Real-World Evidence Study represents a pivotal step toward truly adaptive, responsive, and effective gastrointestinal healthcare.

Subject of Research:
Article Title:
News Publication Date: August 26, 2025
Web References: https://www.gastro.org/, https://latica.ai/, http://gastrohealth.com/, http://allieddigestivehealth.com/
References:
Image Credits:

Keywords: Gastroenterology, Inflammatory Bowel Disease, Ulcerative Colitis, Living Guidelines, Real-World Evidence, Artificial Intelligence, Machine Learning, Natural Language Processing, Electronic Health Records, Clinical Decision Support, Community Health Data, Precision Medicine

IBD is characterized by recurring episodes of inflammation within the gastrointestinal tract, eliciting symptoms such as severe abdominal pain, diarrhea, fatigue, and weight loss. Ulcerative colitis restricts inflammation primarily to the colonic mucosa, whereas Crohn’s disease can affect any layer of the gastrointestinal wall and any part of the digestive tract, from mouth to anus. The persistent inflammatory milieu gradually damages the mucosal barrier and deeper tissue layers, increasing not only patient morbidity but also lifetime risk for colorectal carcinoma. Traditional therapies largely rely on broad immunosuppression, which while mitigating symptoms can sometimes compromise systemic immunity, underscoring a critical need for targeted interventions.

In an extensive research effort led by Prof. Ahmed Hegazy at Charité’s Department of Gastroenterology, Infectiology and Rheumatology, the molecular underpinnings driving chronic inflammation in IBD have been delineated with unprecedented clarity. The team identified a deleterious interaction between two immune messengers: Interleukin-22 (IL-22) and oncostatin M (OSM). While IL-22 generally serves a protective function by sustaining the intestinal epithelial barrier integrity and promoting tissue repair, it paradoxically also primes the gut lining for heightened responsiveness to oncostatin M by increasing the abundance of OSM receptors on gut cells. This synergistic interplay precipitates an uncontrolled inflammatory cascade.

The inflammatory signaling orchestrated by OSM, a cytokine produced by activated immune cells, initiates and perpetuates a hyperactive immune environment by triggering downstream inflammatory agents. Interestingly, the research revealed that patients with elevated OSM expression levels exhibited resistance to established IBD treatments, suggesting that OSM could serve as a prognostic biomarker for identifying individuals at risk of therapeutic non-responsiveness. This insight holds immense clinical potential in guiding personalized medicine approaches for IBD management.

Utilizing sophisticated single-cell RNA sequencing technologies, Hegazy’s team catalogued the cellular composition and receptor expression profiles within inflamed intestinal tissues in both animal models and patient biopsies. These analyses uncovered a conspicuous enrichment of diverse cell populations exhibiting heightened OSM receptor density in inflamed gut areas compared to healthy counterparts. Furthermore, this OSM receptor upregulation was markedly amplified where IL-22 signaling was elevated, confirming the mutually reinforcing nature of these cytokines in driving chronic gut inflammation.

To directly explore potential therapeutic avenues, experimental blockade of OSM receptor activity was employed in preclinical models. Remarkably, inhibiting this receptor-ligand interaction significantly attenuated intestinal inflammation and reduced the incidence and progression of colorectal tumors arising in the context of chronic inflammation. These findings illuminate the critical role that the IL-22/OSM axis plays not only in perpetuating immune dysregulation but also in facilitating tumor-promoting microenvironments.

Importantly, the researchers identified a selective accumulation of OSM receptor–positive cells in tumor-adjacent tissues from colorectal cancer patients with a history of chronic intestinal inflammation, a pattern not observed in non-inflamed healthy tissues. This spatial localization underscores the hypothesis that the IL-22/OSM axis contributes to oncogenic processes, likely by sustaining a pro-inflammatory and tissue-remodeling milieu conducive to malignant transformation.

Dr. Britta Siegmund, Director of the Clinic for Gastroenterology at Charité, emphasized the heterogeneity and complexity of chronic inflammatory bowel diseases across patients, noting that variable cytokine profiles and immune cell interactions complicate therapeutic predictability. The discovery of the IL-22–oncostatin M interplay provides a vital mechanistic framework to classify disease subtypes and stratify patients more accurately based on their underlying pathophysiology and therapeutic responsiveness.

Capitalizing on these translational insights, a clinical trial is already underway to evaluate an antibody targeting the OSM receptor, aiming to disrupt this pathogenic signaling and achieve remission in severely affected IBD patients. This targeted approach marks a departure from broad-spectrum immunosuppression by directly neutralizing a critical inflammation amplifier, potentially reducing side effects and improving efficacy.

The study underscores the vital importance of precision immunology in tackling chronic inflammatory diseases and their sequelae. By elucidating the molecular crosstalk between IL-22 and oncostatin M, these findings herald a promising new era in the management of IBD, offering hope for more durable disease control and prevention of associated bowel cancer.

Financial support for this landmark work was provided by prominent institutions including the European Research Council (ERC), the German Research Foundation (DFG), and the Volkswagen Foundation. Collaborative efforts involving scientists from the German Rheumatism Research Center and industry partners such as Genentech further exemplify the critical synergy of multidisciplinary approaches in driving innovative therapeutic development.

This discovery not only advances our fundamental understanding of immune dysregulation in chronic intestinal diseases but also highlights the complex balancing act within the immune system, where protective mechanisms like IL-22 can, under certain pathological conditions, become complicit in damaging inflammation through their interaction with OSM. Future research may also explore how modulation of this axis impacts the broader systemic immune response and tumor microenvironment interactions.

As the global burden of IBD continues to rise, innovations such as targeting the IL-22–oncostatin M axis illuminate a path forward toward personalized medicine and improved patient outcomes. The convergence of cutting-edge single-cell analytics, targeted molecular therapies, and integrated clinical research heralds a transformative moment in combating this multifaceted disease.

Subject of Research: People

Article Title: The IL-22–oncostatin M axis promotes intestinal inflammation and tumorigenesis

News Publication Date: 07 November 2024

Web References:

• Original publication: https://www.nature.com/articles/s41590-025-02149-z
• Department of Gastroenterology, Infectious Diseases and Rheumatology: https://gastro.charite.de/en/
• AG Hegazy "Inflammatory mechanisms": https://gastro.charite.de/en/research/rg_hegazy
• Press release: https://www.charite.de/en/service/press_reports/artikel/detail/unlocking_predictors_of_success_in_treating_inflammatory_bowel_disease_ibd

References:
Cineus R, et.al. The interleukin 22-oncostatin M axis promotes intestinal inflammation and tumorgenesis. Nature Immunology. 2025 May 30. doi: 10.1038/s41590-025-02149-z

Image Credits: © Charité | Ahmed Hegazy

Keywords:
Inflammatory bowel disease, ulcerative colitis, Crohn’s disease, oncostatin M, interleukin-22, chronic inflammation, cytokines, colorectal cancer, targeted therapy, immune signaling, biomarker, intestinal tumorigenesis

Crohn’s disease, categorized as an inflammatory bowel disease, afflicts millions worldwide and is characterized by chronic inflammation of the gastrointestinal tract. Its unpredictable nature means that at least 80% of diagnosed individuals will undergo surgical intervention at some stage, and distressingly, approximately 40% of these patients will find themselves in need of repeat surgeries within a few years. These repeat surgical procedures often lead to increased morbidity, extended hospital stays, and a significantly diminished quality of life for these patients, predominantly young adults in the prime of their lives.

At the core of this innovative surgical approach is the removal of the mesentery, a structure which supports the intestines and connects them to the abdominal wall. In 2016, it was reclassified as a distinct organ, highlighting its pivotal role not only in abdominal structure but also in the pathophysiology of Crohn’s disease. The mesentery’s removal, which was counterintuitive to previous surgical practices, drastically reduces the necessity for additional surgeries, minimizing recurrence rates down to approximately 4%.

Prior to this methodology, many surgeons adhered to the traditional view that preserving the mesentery during surgery was crucial, despite the considerable challenges associated with its complete removal. The conviction stemmed from a lack of understanding surrounding the mesentery’s potential contributions to disease recurrence. However, recent insights into its biological functions, particularly in relation to Crohn’s disease, have illuminated the dire implications it can pose in cases of pathological conditions.

In a rigorous international trial recently published, a robust evaluation was conducted comparing traditional surgical techniques with the new mesenteric-excision method. The results were compelling; patients undergoing the conventional approach faced a staggering 46% rate of disease relapse, while those who had undergone the new surgical strategy experienced a reduction down to 23%. Moreover, the trial assessed the severity of endoscopic recurrence, revealing that patients whose mesentery was excised experienced a significantly milder form of relapse as opposed to their counterparts.

Professor Coffey stated, “The evidence suggests a landmark shift in how we approach the surgical treatment of Crohn’s disease. Our findings strongly advocate for the incorporation of mesentery removal as a part of the standard operational protocol, which could deliver enhanced long-term outcomes for patients." Such a statement encapsulates not only the innovation of the technique but also the potential for it to become a transformative standard of care within gastroenterology.

The implications of this procedure reach far beyond the surgical theatre. Patients with Crohn’s disease often find themselves navigating profound chronic pain, nutritional deficiencies, and frequent hospital visits. The prospect of reducing the need for repeated hospitalizations and extensive medical treatments provides a beacon of hope for many, especially for younger demographics who are often embarking on significant life milestones such as careers and family formation.

Despite nearly a century of research aimed at developing successful pharmaceutical interventions for Crohn’s disease, progress has been cruelly limited, necessitating a re-evaluation of surgical options. The pivotal discoveries regarding the mesentery’s role in disease pathology now provide a renewed sense of optimism, suggesting a tangible solution to combat the debilitating hold of this condition.

The publication of findings in reputable journals like Gastroenterology underscores both the scientific rigor and the potential real-world impact of this research. As further studies and trials are conducted to solidify these findings, there is a palpable excitement within the medical community. The hope is that this surgical technique might soon be adopted as commonplace in medical practices worldwide.

In summary, the novel surgical approach to Crohn’s disease, emerging from the depths of Irish innovation, delivers a powerful message: that understanding organ functions beyond traditional definitions can significantly enhance patient care and outcomes. The validation seen through the international trial represents not only a victory for the researchers but serves as a significant step forward in gastrointestinal surgical practices, potentially bringing a wave of change that offers patients the relief they deserve.

In anticipation of widespread implementation, it is imperative that the medical community remains vigilant in monitoring long-term outcomes related to this surgical strategy, ensuring a thorough understanding of its effectiveness as well as any unforeseen complications that may arise. The journey towards better managing Crohn’s disease is underway, driven by innovative techniques and a deepened understanding of human anatomy that redefines old paradigms.

Subject of Research: People
Article Title: Postoperative Endoscopic Outcomes in the MESOCOLIC Trial Investigating Mesenteric-Based Surgery for Crohn’s Disease
News Publication Date: 9-Jan-2025
Web References: Gastroenterology Journal
References: DOI
Image Credits: Credit: University of Limerick, Ireland
Keywords: Crohn’s disease, surgical innovation, mesentery removal, gastroenterology, inflammatory bowel disease, health care advancements, surgical outcomes, patient well-being.

The researchers employed the Health Resources & Services Administration’s Area Health Resources data regarding U.S. physician workforce distribution in conjunction with 2020 U.S. Census data to evaluate county-level access to gastroenterologists. The analysis revealed that over two-thirds of the 3,149 counties across the United States lack a single gastroenterologist, leaving an alarming 49 million individuals without accessible care options in their locality. The study also highlights that 17% of counties have fewer than five gastroenterologists, exacerbating the issue of access in some regions.

In discussing the implications of these findings, Dr. Xiaohan Ying, a clinical associate in medicine at Weill Cornell Medicine, noted that while the national landscape may suggest adequate access—given that most Americans are within driving distance of a gastroenterologist—the reality is that underserved areas are in dire need of increased healthcare provisions. This disparity is particularly pressing considering that the demand for gastroenterological services is likely to escalate with an aging population, which typically exhibits higher incidences of digestive-related health issues.

The analysis further indicated that approximately 80% of the counties devoid of gastroenterology services are situated in non-metropolitan regions, where residents often belong to older demographic groups that require specialized care. These areas are characterized not just by their geographical isolation, but also by economic disadvantages, including lower median household incomes, higher rates of uninsured individuals, and demographics skewed toward a higher percentage of white residents compared to regions with better healthcare access. Alarmingly, states like Alaska, North Dakota, and Wyoming demonstrate the lowest ratios of gastroenterologists per 100,000 inhabitants, contrasting sharply with Massachusetts, Connecticut, and New York, which rank among the highest.

Another concerning aspect of the study is the age demographics of practicing gastroenterologists. It was documented that a significant portion of gastroenterologists in non-metropolitan areas—over two-thirds—are older than 55 years, and nearly half are over 65. Dr. Leah Yao, another key contributor to the study, emphasized that as these experienced specialists approach retirement, rural regions may face increasingly dire accessibility challenges, further entrenching the disparities in healthcare access that already exist in less populated areas.

Acknowledging these disparities, the researchers stress the importance of innovative solutions to bridge the gap in gastroenterological care. Dr. Arun Jesudian, a co-senior author of the study, suggested that advanced practice clinicians could play a vital role in augmenting the availability of gastrointestinal health services in underserved regions. Their involvement may provide an essential resource in mitigating the growing need for specialty care among populations that are geographically isolated. Furthermore, the introduction of incentive programs—such as loan repayment or improved reimbursement strategies for clinicians practicing in rural settings—could stimulate interest in working in these areas, helping to enhance the community’s overall health landscape.

The disparity in healthcare access poses questions not just at the clinical level but also at the policy-making level. There is an urgent need for targeted interventions that will expand the gastroenterologist workforce in order to address the unmet needs prevalent in rural and economically disadvantaged communities. Comprehensive policy strategies are essential to ensure that all Americans, regardless of their geographic location, have equal access to crucial medical services.

As the healthcare landscape evolves alongside demographic shifts, it is imperative that stakeholders, including policymakers and healthcare institutions, prioritize the improvement of access to specialty care. Such measures will not only benefit individuals suffering from gastroenterological conditions but will also contribute to the long-term health and well-being of entire communities. The findings from this study bring to light a pressing need for action and awareness regarding disparities in healthcare access, especially within the realm of gastroenterology.

As our understanding of healthcare disparities deepens, it becomes increasingly clear that concerted efforts must be made to ensure equitable access to gastroenterological services. Only through a united approach—encompassing policy changes, workforce development, and community-focused initiatives—can we hope to alleviate the burden of unmet needs in gastroenterology, particularly in our most vulnerable populations.

Moving forward, continued research and advocacy will be critical in addressing the systemic barriers that hinder access to digestive health care in America. By placing a spotlight on these issues, we can work towards building a healthcare system that is more inclusive, equitable, and responsive to the needs of all patients.

Subject of Research: Access to Gastroenterological Care in Rural America
Article Title: Geographic Disparities in Access to Gastroenterologists: A National Study
News Publication Date: February 6, 2025
Web References: Gastroenterology Journal
References: Weill Cornell Medicine Study
Image Credits: N/A
Keywords: Gastroenterology, Public Health, Rural Health Disparities, Healthcare Access, Aging Population, Workforce Development, Policy Interventions.